CA3018180C - Pyrimidines and variants thereof, and uses therefor - Google Patents

Pyrimidines and variants thereof, and uses therefor Download PDF

Info

Publication number
CA3018180C
CA3018180C CA3018180A CA3018180A CA3018180C CA 3018180 C CA3018180 C CA 3018180C CA 3018180 A CA3018180 A CA 3018180A CA 3018180 A CA3018180 A CA 3018180A CA 3018180 C CA3018180 C CA 3018180C
Authority
CA
Canada
Prior art keywords
compound
formula
mmol
mixture
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3018180A
Other languages
English (en)
French (fr)
Other versions
CA3018180A1 (en
Inventor
Ronald Charles Hawley
Prabha Ibrahim
Anthony P. FORD
Joel R. Gever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afferent Pharmaceuticals Inc
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of CA3018180A1 publication Critical patent/CA3018180A1/en
Application granted granted Critical
Publication of CA3018180C publication Critical patent/CA3018180C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA3018180A 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor Active CA3018180C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
US62/313,334 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (2)

Publication Number Publication Date
CA3018180A1 CA3018180A1 (en) 2017-09-28
CA3018180C true CA3018180C (en) 2024-02-20

Family

ID=59900805

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3018180A Active CA3018180C (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Country Status (11)

Country Link
US (2) US10662162B2 (https=)
EP (1) EP3433258B1 (https=)
JP (1) JP6902045B2 (https=)
KR (1) KR102377805B1 (https=)
CN (1) CN108779119B (https=)
AU (1) AU2017237929B2 (https=)
CA (1) CA3018180C (https=)
MA (1) MA44489A (https=)
MX (1) MX384368B (https=)
RU (1) RU2760733C2 (https=)
WO (1) WO2017165255A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43821A (fr) 2016-03-14 2018-11-28 Afferent Pharmaceuticals Inc Pyrimidines et variantes de celles-ci, et leurs utilisations
MA44489A (fr) 2016-03-25 2019-01-30 Afferent Pharmaceuticals Inc Pyrimidines et variants de celles-ci, et leurs utilisations
WO2018116139A1 (en) 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
WO2018118668A1 (en) * 2016-12-20 2018-06-28 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a p2x3 antagonist
JP7207634B2 (ja) * 2017-11-01 2023-01-18 ベイジン タイド ファーマシューティカル カンパニー リミテッド P2x3及び/又はp2x2/3受容体アンタゴニスト、それを含む医薬組成物及びその使用
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
SG11202111960PA (en) 2019-04-30 2021-12-30 Beijing Tide Pharmaceutical Co Ltd Method for treating endometriosis-associated pain by using diaminopyrimidine compound
KR102847760B1 (ko) 2019-04-30 2025-08-18 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도
EP3960179B1 (en) * 2019-04-30 2026-03-18 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
JP7538153B2 (ja) 2019-06-06 2024-08-21 ベイジン タイド ファーマシューティカル カンパニー リミテッド P2x3及び/又はp2x2/3受容体アンタゴニスト、それを含む医薬組成物及びその使用
CN120058573B (zh) * 2025-04-29 2025-12-23 潍坊学院 一种1-三溴甲基磺酰基萘及其衍生物的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
AU4198400A (en) * 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
CN1930135B (zh) * 2004-03-05 2011-12-28 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶
CA2620129C (en) * 2005-09-01 2014-12-23 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
CA2619919C (en) * 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025900A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
JP4850914B2 (ja) * 2005-09-01 2012-01-11 エフ.ホフマン−ラ ロシュ アーゲー P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン
AU2007304280B2 (en) * 2006-10-04 2013-01-31 F. Hoffmann-La Roche Ag Process for synthesis of phenoxy diaminopyrimidine derivatives
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
RU2010121763A (ru) * 2007-10-31 2011-12-10 Ниссан Кемикал Индастриз, Лтд. (Jp) Производные пиридазинона и ингибиторы р2х7 рецептора
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
RU2650118C2 (ru) * 2013-08-23 2018-04-09 Афферент Фармасьютикалз Инк. Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
US10195198B2 (en) * 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
MA43821A (fr) * 2016-03-14 2018-11-28 Afferent Pharmaceuticals Inc Pyrimidines et variantes de celles-ci, et leurs utilisations
MA44489A (fr) * 2016-03-25 2019-01-30 Afferent Pharmaceuticals Inc Pyrimidines et variants de celles-ci, et leurs utilisations

Also Published As

Publication number Publication date
EP3433258B1 (en) 2023-07-19
MX2018011622A (es) 2019-03-28
MX384368B (es) 2025-03-14
KR102377805B1 (ko) 2022-03-22
CN108779119B (zh) 2022-02-08
CN108779119A (zh) 2018-11-09
AU2017237929A1 (en) 2018-09-13
US10662162B2 (en) 2020-05-26
RU2760733C2 (ru) 2021-11-30
MA44489A (fr) 2019-01-30
AU2017237929B2 (en) 2021-04-15
EP3433258A1 (en) 2019-01-30
JP6902045B2 (ja) 2021-07-14
RU2018137032A (ru) 2020-04-27
RU2018137032A3 (https=) 2020-05-22
EP3433258A4 (en) 2019-10-30
WO2017165255A1 (en) 2017-09-28
US20200239421A1 (en) 2020-07-30
BR112018069105A2 (pt) 2019-01-29
US20190055202A1 (en) 2019-02-21
US11230532B2 (en) 2022-01-25
JP2019510025A (ja) 2019-04-11
CA3018180A1 (en) 2017-09-28
KR20180128015A (ko) 2018-11-30

Similar Documents

Publication Publication Date Title
CA3018180C (en) Pyrimidines and variants thereof, and uses therefor
AU2017233841B2 (en) Pyrimidines and variants thereof, and uses therefor
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
AU2010332969B2 (en) New CCR2 receptor antagonists and uses thereof
EP2183224B1 (en) 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis
CN115340555A (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
US9725445B2 (en) Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors
KR20150128722A (ko) 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드
WO2016169421A1 (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
TW202519211A (zh) 經取代之胺基吡啶化合物及用其治療疾病之方法
CN109563033B (zh) 脂族脯氨酰胺衍生物
TW201726651A (zh) 2,3,4,5-四氫吡啶-6-胺衍生物
BR112018069105B1 (pt) Composto de pirimidina, composição e uso do mesmo
JP2017533929A (ja) プロキネチシン介在消化器疾患を治療するためのスルホニルピペリジン誘導体及びその使用
CA3016773C (en) Pyrimidines and variants thereof, and uses therefor
HK40061670A (en) Compounds and compositions for treating conditions associated with apj receptor activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220318

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209